RFA-DE-23-010: The Role of Dentistry in the Prevention of Opioid Drug Misuse and Abuse (UG3/UH3 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $400,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 10, 2022.
From the official notice on Grants.gov, last changed March 2, 2022. Checked November 7, 2026.
- Award ceiling$400,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsOptional
- Funded byNIDCR
- Median yearly award$1.0 million
- Typical project length3.5 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-DE-23-010 were run by National Institute of Dental and Craniofacial Research (NIDCR, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DE-23-010 in the NIH Guide.
Key dates
| Posted | March 2, 2022 |
|---|---|
| Deadline | May 10, 2022 |
| Archived by Grants.gov | June 15, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.0 million; it allows up to $400,000 per award.
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) is soliciting applications to support the planning and implementation of research to establish effective interventions or programs to manage, reduce, or prevent opioid drug misuse and align the opioid prescribing practices of dental professionals with scientific evidence.
Funded under RFA-DE-23-010 so far
NIH funded 2 projects under RFA-DE-23-010 in fiscal 2023 to 2026, at 1 institution. The median yearly award was $1.0 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Empowering dentists to reduce opioid prescriptions to young people | University of Kentucky | 2026 | $1.1 million |
| Empowering dentists to reduce opioid prescriptions to young people | University of Kentucky | 2023 | $580,179 |
Who has won Oral Diseases and Disorders Research grants before
From fiscal 2021 to 2025, Oral Diseases and Disorders Research (93.121) awarded $1.9 billion across 2,263 grant awards, an average of $818,037 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 76 | $89.2 million |
| The Regents of the University of California, San Francisco | California | 84 | $80.5 million |
| University of Southern California | California | 41 | $78.6 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 58 | $55.9 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 66 | $51.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DE-23-010 still open?
No. It closed on May 10, 2022.
Who can apply for The Role of Dentistry in the Prevention of Opioid Drug Misuse and Abuse (UG3/UH3 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for The Role of Dentistry in the Prevention of Opioid Drug Misuse and Abuse (UG3/UH3 Clinical Trial Optional)?
Closed May 10, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $400,000 each.
Who has been funded under RFA-DE-23-010?
NIH RePORTER lists 2 projects funded under RFA-DE-23-010 in fiscal 2023 to 2026, at 1 institution.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)